X linked hypophosphataemia: Treatment, height gain, and nephrocalcinosis

G. Reusz, P. F. Hoyer, M. Lucas, H. P. Krohn, J. H H Ehrich, J. Brodehl

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

The clinical data of 18 patients with X linked hypophosphataemia were analysed retrospectively. The height data were expressed as SD scores. There was no difference in the final height of patients treated with vitamin D (or 1,25-dihydroxyvitamin D) and phosphate for at least two years (n = 12) and that of 16 hypophosphataemic family members who had never been treated. The mean final SD score (-2.07) of treated patients, however, was significantly higher than the value before treatment (-2.79), which indicated an average absolute height gain of 4-4.5 cm compared with the expected height values. Six of the treated patients developed ultrasonographically detectable nephrocalcinosis with normal renal function. The daily phosphate intake and excretion of patients with nephrocalcinosis was significantly higher than that of patients with normal renal morphology. There was no difference in the doses of vitamin D between the two groups. The average urinary calcium:creatinine ratio of the two groups was similar to and below the hypercalciuric 0.6 mmol:mmol limit. The group with nephrocalcinosis, however, had a higher incidence of hypercalciuric episodes than the group without nephrocalcinosis (12 in 130 observations compared with six in 334 observations, respectively). The benefits and risks of treatment of patients with X linked hypophosphataemia must be further evaluated. The high dose of phosphate seems to be an important factor in the development of nephrocalcinosis in this group of patients.

Original languageEnglish
Pages (from-to)1125-1128
Number of pages4
JournalArchives of Disease in Childhood
Volume65
Issue number10
Publication statusPublished - 1990

Fingerprint

Nephrocalcinosis
Phosphates
Therapeutics
Vitamin D
Kidney
Creatinine
Calcium
Incidence

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Reusz, G., Hoyer, P. F., Lucas, M., Krohn, H. P., Ehrich, J. H. H., & Brodehl, J. (1990). X linked hypophosphataemia: Treatment, height gain, and nephrocalcinosis. Archives of Disease in Childhood, 65(10), 1125-1128.

X linked hypophosphataemia : Treatment, height gain, and nephrocalcinosis. / Reusz, G.; Hoyer, P. F.; Lucas, M.; Krohn, H. P.; Ehrich, J. H H; Brodehl, J.

In: Archives of Disease in Childhood, Vol. 65, No. 10, 1990, p. 1125-1128.

Research output: Contribution to journalArticle

Reusz, G, Hoyer, PF, Lucas, M, Krohn, HP, Ehrich, JHH & Brodehl, J 1990, 'X linked hypophosphataemia: Treatment, height gain, and nephrocalcinosis', Archives of Disease in Childhood, vol. 65, no. 10, pp. 1125-1128.
Reusz G, Hoyer PF, Lucas M, Krohn HP, Ehrich JHH, Brodehl J. X linked hypophosphataemia: Treatment, height gain, and nephrocalcinosis. Archives of Disease in Childhood. 1990;65(10):1125-1128.
Reusz, G. ; Hoyer, P. F. ; Lucas, M. ; Krohn, H. P. ; Ehrich, J. H H ; Brodehl, J. / X linked hypophosphataemia : Treatment, height gain, and nephrocalcinosis. In: Archives of Disease in Childhood. 1990 ; Vol. 65, No. 10. pp. 1125-1128.
@article{3cccbbc2c33f4808b988b9e884b4ffa2,
title = "X linked hypophosphataemia: Treatment, height gain, and nephrocalcinosis",
abstract = "The clinical data of 18 patients with X linked hypophosphataemia were analysed retrospectively. The height data were expressed as SD scores. There was no difference in the final height of patients treated with vitamin D (or 1,25-dihydroxyvitamin D) and phosphate for at least two years (n = 12) and that of 16 hypophosphataemic family members who had never been treated. The mean final SD score (-2.07) of treated patients, however, was significantly higher than the value before treatment (-2.79), which indicated an average absolute height gain of 4-4.5 cm compared with the expected height values. Six of the treated patients developed ultrasonographically detectable nephrocalcinosis with normal renal function. The daily phosphate intake and excretion of patients with nephrocalcinosis was significantly higher than that of patients with normal renal morphology. There was no difference in the doses of vitamin D between the two groups. The average urinary calcium:creatinine ratio of the two groups was similar to and below the hypercalciuric 0.6 mmol:mmol limit. The group with nephrocalcinosis, however, had a higher incidence of hypercalciuric episodes than the group without nephrocalcinosis (12 in 130 observations compared with six in 334 observations, respectively). The benefits and risks of treatment of patients with X linked hypophosphataemia must be further evaluated. The high dose of phosphate seems to be an important factor in the development of nephrocalcinosis in this group of patients.",
author = "G. Reusz and Hoyer, {P. F.} and M. Lucas and Krohn, {H. P.} and Ehrich, {J. H H} and J. Brodehl",
year = "1990",
language = "English",
volume = "65",
pages = "1125--1128",
journal = "Archives of Disease in Childhood",
issn = "0003-9888",
publisher = "BMJ Publishing Group",
number = "10",

}

TY - JOUR

T1 - X linked hypophosphataemia

T2 - Treatment, height gain, and nephrocalcinosis

AU - Reusz, G.

AU - Hoyer, P. F.

AU - Lucas, M.

AU - Krohn, H. P.

AU - Ehrich, J. H H

AU - Brodehl, J.

PY - 1990

Y1 - 1990

N2 - The clinical data of 18 patients with X linked hypophosphataemia were analysed retrospectively. The height data were expressed as SD scores. There was no difference in the final height of patients treated with vitamin D (or 1,25-dihydroxyvitamin D) and phosphate for at least two years (n = 12) and that of 16 hypophosphataemic family members who had never been treated. The mean final SD score (-2.07) of treated patients, however, was significantly higher than the value before treatment (-2.79), which indicated an average absolute height gain of 4-4.5 cm compared with the expected height values. Six of the treated patients developed ultrasonographically detectable nephrocalcinosis with normal renal function. The daily phosphate intake and excretion of patients with nephrocalcinosis was significantly higher than that of patients with normal renal morphology. There was no difference in the doses of vitamin D between the two groups. The average urinary calcium:creatinine ratio of the two groups was similar to and below the hypercalciuric 0.6 mmol:mmol limit. The group with nephrocalcinosis, however, had a higher incidence of hypercalciuric episodes than the group without nephrocalcinosis (12 in 130 observations compared with six in 334 observations, respectively). The benefits and risks of treatment of patients with X linked hypophosphataemia must be further evaluated. The high dose of phosphate seems to be an important factor in the development of nephrocalcinosis in this group of patients.

AB - The clinical data of 18 patients with X linked hypophosphataemia were analysed retrospectively. The height data were expressed as SD scores. There was no difference in the final height of patients treated with vitamin D (or 1,25-dihydroxyvitamin D) and phosphate for at least two years (n = 12) and that of 16 hypophosphataemic family members who had never been treated. The mean final SD score (-2.07) of treated patients, however, was significantly higher than the value before treatment (-2.79), which indicated an average absolute height gain of 4-4.5 cm compared with the expected height values. Six of the treated patients developed ultrasonographically detectable nephrocalcinosis with normal renal function. The daily phosphate intake and excretion of patients with nephrocalcinosis was significantly higher than that of patients with normal renal morphology. There was no difference in the doses of vitamin D between the two groups. The average urinary calcium:creatinine ratio of the two groups was similar to and below the hypercalciuric 0.6 mmol:mmol limit. The group with nephrocalcinosis, however, had a higher incidence of hypercalciuric episodes than the group without nephrocalcinosis (12 in 130 observations compared with six in 334 observations, respectively). The benefits and risks of treatment of patients with X linked hypophosphataemia must be further evaluated. The high dose of phosphate seems to be an important factor in the development of nephrocalcinosis in this group of patients.

UR - http://www.scopus.com/inward/record.url?scp=0025187652&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025187652&partnerID=8YFLogxK

M3 - Article

C2 - 2248503

AN - SCOPUS:0025187652

VL - 65

SP - 1125

EP - 1128

JO - Archives of Disease in Childhood

JF - Archives of Disease in Childhood

SN - 0003-9888

IS - 10

ER -